Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The incidence of Barrett adenocarcinoma is increasing substantially and was estimated at 2.8 cases per 100 000 people in the United States in 2010.1 Given the premalignant potential of Barrett intestinal metaplasia, it would be logical to simply eliminate preneoplastic tissue. Indeed, if Barrett esophagus was a focally localized, raised, and easily recognizable lesion (ie, polyp), endoscopic removal would be a relatively easy task, and there would be no discussion about how to prevent neoplastic progression in these patients.
Mönkemüller K. Radiofrequency Ablation for Barrett Esophagus With Confirmed Low-Grade Dysplasia. JAMA. 2014;311(12):1205-1206. doi:10.1001/jama.2014.2512